Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,202 people get ARNA articles and Market Currents by email alert.
Get email alerts on ARNA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Arena's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012 • 10 Comments
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
Arena Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Arena Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptWed, May 7, 2008 • 1 Comment
-
Arena Pharmaceuticals Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
Arena Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 17, 2007
-
PR Newswire (May 10, 2013)
-
at CNBC.com (May 2, 2013)
-
PR Newswire (May 2, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Apr 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 6, 2013)
-
at CNBC.com (Feb 5, 2013)
-
PR Newswire (Jan 2, 2013)
-
at CNBC.com (Dec 17, 2012)
-
at MarketWatch.com (Dec 14, 2012)
-
PR Newswire (Dec 6, 2012)
-
PR Newswire (Nov 21, 2012)
ARNA vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas:... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, August 15, 2012, 9:33 AM Arena Pharma (ARNA +4.1%) adds to sharp gains from yesterday as LifeSci Advisors publishes an upbeat note about the stock. LifeSci's main points include Arena possibly receiving a $1.2B one-time purchase price adjustment from its partner Eisai based on net sales of diet drug Belviq. 7 Comments [On the Move, Healthcare]
- Thursday, August 9, 2012, 4:22 PM More on Arena Pharmaceuticals (ARNA): Q2 EPS comes up short but beats top line estimates. Total revenue jumped over 500% Y/Y, however the increase was primarily the result of the $20M milestone payment earned under its marketing and supply agreement with Japanese drug maker Eisai. Bottom line results were hit by higher losses from the revaluation of derivative liabilities. Shares -3.6% AH. 7 Comments [Healthcare, Earnings, On the Move]
- Thursday, August 9, 2012, 4:13 PM Arena Pharmaceuticals (ARNA): Q2 EPS loss of -$0.12 misses by $0.04. Revenue of $22M (+566% Y/Y) beats by $14.6M. (PR) Shares -0.8% AH. 5 Comments [Healthcare, Earnings]
- Thursday, August 9, 2012, 12:10 AM Notable earnings after Thursday’s close: AGO, ARNA, CFN, DAR, DNN, DV, EVEP, FIO, JWN, LGF, MDVN, NVDA, PSEC, RNDY, SLW, SPRD Comment! [Earnings]
- Wednesday, August 8, 2012, 5:35 PM Notable earnings after Thursday’s close: AGO, ARNA, CFN, DAR, DNN, DV, EVEP, FIO, JWN, LGF, MDVN, NVDA, PSEC, RNDY, SLW, SPRD 3 Comments [Earnings]
- Monday, July 30, 2012, 11:43 AM Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai (ESALY.PK), which will market the pill in the U.S. and apply for authorization in other countries in the Americas. SA author Red Acre Investments notes that what is not explicitly stated is that Eisai, not Arena, will run all of the pediatric and cardiovascular outcome trials that are required under Belviq's FDA approval letter (.pdf). (PR) 1 Comment [Healthcare]
- Wednesday, July 18, 2012, 1:35 PM A bevy of Street analysts weigh in on Vivus' (VVUS +11%): Cowen says Qsymia has "considerably better" efficacy over Arena's (ARNA -7.5%) Belviq. Brean Murray says the approval came clean, without any harsh restrictions. Jefferies - after initially being negative on the stock - calls the FDA decision a "major win" for the company and upgrades the shares to Underperform. Wells Fargo is a bit more cautious, saying that despite the big win, the company still faces reimbursement challenges, a restrictive distribution network, and patient compliance. 18 Comments [Healthcare, On the Move]
-
Wednesday, July 18, 2012, 9:10 AM
Premarket gainers: VVUS +17%. GALE +9%. EMC +7%. VMW +7%.
Losers: ROVI -31%. STEM -9%. SBH -8%. ARNA -7%. SSNC -7%. TSLA -7%. OMEX -4%. 2 Comments [On the Move] - Wednesday, July 18, 2012, 8:40 AM Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%. 13 Comments [On the Move, Healthcare]
- Tuesday, July 17, 2012, 8:14 PM Other drug stocks reacting after hours to the FDA's approval of Vivus' (VVUS) Qnexa/Qsymia: OREX +6.4%, ARNA -6.7%. 26 Comments [Healthcare, On the Move]
- Wednesday, July 11, 2012, 10:10 AM Jim Cramer dampens some of the excitement surrounding Arena (ARNA -4.1%), saying that the company's Belviq diet drug won't make as much money as people think. Cramer notes that Arena will receive just 40% of the revenues from treatment, which is anyway not as effective as initially thought, nor as good as Vivus' (VVUS) yet-to-be-approved Qnexa. 25 Comments [Healthcare, On the Move]
- Tuesday, July 10, 2012, 1:35 PM Arena Pharmaceuticals (ARNA) +4.3% amid heavy trading and continuing the upward trend it's enjoyed since April over excitement about its Belviq obesity treatment. SA author Efsinvestment says that with a Relative Strength Index of 65%, the stock needs a breather, although it will be worth buying after any pullback. 2 Comments [Healthcare, On the Move]
- Monday, July 9, 2012, 10:56 AM Arena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing potential M&A interest in the drug developer, thanks to recent FDA approval of its Belviq weight-loss drug. Analysts speculate GlaxoSmithKline (currently divesting a diet pill line) or Japan's Eisai (the U.S. launch partner for Belviq) could make a bid. 25.3% of Arena's float was shorted as of June 15. 6 Comments [Healthcare, On the Move, M&A, Quick Ideas]
- Thursday, July 5, 2012, 8:58 AM Arena (ARNA -0.7%) rewards the VP of its regulatory affairs, Craig Audet, for his role in the company receiving FDA approval for weight-loss drug Belviq by promoting him to Senior VP, Operations and Head of Global Regulatory Affairs. Audet's new role will also include investor relations and alliance management. (PR) 3 Comments [Healthcare]
- Monday, July 2, 2012, 12:57 PM Arena Pharmaceuticals (ARNA -3.6%) continues to give back some of the massive gains it enjoyed after the FDA approved its weight-loss drug Belviq. Orexigen, which surged on the news as well, is -4.7%. Vivus, though, (VVUS +1.5%) is still climbing ahead of an FDA decision on its Qnexa diet drug on July 17. 6 Comments [On the Move, Healthcare]
- Thursday, June 28, 2012, 12:33 PM Orexigen Therapeutics (OREX +13.2%) soars again today on the back of the FDA's approval of Arena Pharmaceuticals (ARNA) Belviq weight loss drug. JPMorgan ups the stock to Overweight, saying it "stands to be the biggest beneficiary" as approval for its own weight loss drug, Contrave, is still far off, which leaves a valuation gap with rivals whose drugs are closer to approval. 32 Comments [Healthcare, On the Move]
-
Day Trader001
Good money to be made this week on the $ARNA bounce once again! This is better than an atm machine. - View all 2 replies
-
-
Day Trader001: "No News" as usual! This is a normal dip. Check out Recognia's chart info on Fidelity! Wow, Great move on BBRY!! good thing ya bailed!
-
Ryan Mallory
Fuinhaz Setups for March 20 2013 | $ARNA $BBRY $BIDU $GEVO $ITRN $SPLS | SharePlanner http://bit.ly/11f2tGd - View all 0 replies
-
- View all 1 replies
-
RSI Raistlin: closed $ARNA calls for .78...yea left some money on the table but in and out im happy with the profit
LATEST REPLIES
-
Joe Springer
Here's the latest $33,000 article, we stand at $35,814.50 http://seekingalpha.com/a/kltb $PSTI $SPPI $ARNA $ACI $MNKD $IBIO $ATRS #Sandy - View all 3 replies
-
Joe Springer: Hi IV, May 25 was start, I try to limit the trades so that it is replicable, 2 month average per trade about: http://seekingalpha.com/p/e7pf -
-
Day Trader001
Anyone playing VVUS & ARNA upcoming earnings? Small buy today, 10 ARNA 11-17 $7.00 Calls for 1.58 VVUS still falling! - View all 4 replies
-
-
-
- View all 17 replies
-
phemale60: Awwwright, sounds good. When lived in WA camped out and Weyerhaeuser clear cut so many trees there were only stumps everywhere. Really sad -
-
- View all 18 replies
-
-
phemale60: Funny, finally won game aft. a week when stuck in our office bldg. elevator for nearly an hour -so focused! Market looks good today so far
-
- View all 6 replies
-
-
Randy_J.: @Phemale, you are correct there are no sure things! Should there be only one world wide weight loss drug it will surely rocket!
-
- View all 11 replies
-
Day Trader001: Phe, did ya dump it for the quarter? I got great gain on BIDU today holding out for another $10-$15 before cashing out, only have 900 shares -
-
- View all 17 replies
-
Boatyzaffa: my trade. I believe it is a valuable exercise for a trader to defend his/her trades. If there is a better way I am seeking it and would... -
Boatyzaffa: ...hope you will share it with me. Best of luck to you in your trading endeavors
-
Day Trader001
Don't look now, ARNA 's is going up! "Time for the negative articles to start rolling out" - View all 11 replies
-
phemale60: Then got second acct. averaging $24 - losing $ on that while gaining on $9 - making me nuts. Day, just got new smartphone but not on cruise -
-
Day Trader001
Went to Wal-Mart late last night (had bad dreams after) anyway, heard they were buying ARNA & VVUS ! To be passed out free by the greeters! - View all 7 replies
-
-
-
- View all 10 replies
-
phemale60: Just saw CNN special about the dollar stores last night -- they are doing great. Didn't know which was was best. Thanks. -
Day Trader001: DLTR just split about a month ago it got up to $110.00, my sister in law got in on it at $20.00! That article was pretty informative.
-
- View all 2 replies
-
-
LEIGHDIST: hoang6 is right there is nothing that says buyout right now, its based on the net sales , possibly receiving a $1.2B






